Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Zoetis Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.69, while Zoetis Inc trades at $73.91 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals.
| SJNK | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $25.63 | $150.61 |
52-Week Low | $24.67 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.70 with minimal daily movement (-0.04%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral. The ETF continues its regular dividend distributions, with recent payments of $0.14-0.15 per share. Institutional activity shows mixed sentiment with some firms reducing positions.
The outlook remains cautious given the bearish technical signals and institutional selling pressure. While the ETF provides consistent dividend income, high-yield bond markets face headwinds from potential yield increases and economic uncertainty. Investors should weigh the income generation against credit risk exposure in the current market environment.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
